Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience

dc.contributor.authorBadilla‑Porras, R
dc.contributor.authorEcheverri‑McCandless, A
dc.contributor.authorWeimer, J. M
dc.contributor.authorUlate‑Campos, A
dc.contributor.authorSoto‑Rodríguez, A
dc.contributor.authorGutiérrez‑Mata, A
dc.contributor.authorHernández‑Con, L
dc.contributor.authorBogantes‑Ledezma, S
dc.contributor.authorBalmaceda‑Meza, A
dc.contributor.authorBrudvig, J
dc.contributor.authorSanabria‑Castro, A
dc.date.accessioned2025-07-14T20:47:35Z
dc.date.available2025-07-14T20:47:35Z
dc.date.issued2022
dc.descriptionARTICULO
dc.description.abstractBackground: Commonly known as Batten disease, the neuronal ceroid lipofuscinoses (NCLs) are a genetically heterogeneous group of rare pediatric lysosomal storage disorders characterized by the intracellular accumulation of autofluorescent material (known as lipofuscin), progressive neurodegeneration, and neurological symptoms. In 2002, a disease-causing NCL mutation in the CLN6 gene was identified (c.214G > T) in the Costa Rican population, but the frequency of this mutation among local Batten disease patients remains incompletely characterized, as do clinical and demographic attributes for this rare patient population. Objective: To describe the main sociodemographic and clinical characteristics of patients with a clinical diagnosis for Batten Disease treated at the National Children’s Hospital in Costa Rica and to characterize via molecular testing their causative mutations. Methods: DNA extracted from buccal swabs was used for CLN6 gene sequencing. Participants’ sociodemographic and clinical characteristics were also obtained from their medical records. Results: Nine patients with a clinical diagnosis of Batten disease were identified. Genetic sequencing determined the presence of the previously described Costa Rican homozygous mutation in 8 of 9 cases. One patient did not have mutations in the CLN6 gene. In all cases where the Costa Rican CLN6 mutation was present, it was accompanied by a substitution in intron 2. Patients were born in 4 of the 7 Costa Rican provinces, with an average onset of symptoms close to 4 years of age. No parental consanguinity was present in pedigrees. Initial clinical manifestations varied between patients but generally included: gait disturbances, language problems, visual impairment, seizures and psychomotor regression. Cortical and cerebellar atrophy was a constant finding when neuroimaging was performed. Seizure medication was a common element of treatment regimens. Conclusions: This investigation supports that the previously characterized c.214G > T mutation is the most common causative NCL mutation in the Costa Rican population. This mutation is geographically widespread among Costa Rican NCL patients and yields a clinical presentation similar to that observed for CLN6 NCL patients in other geographies
dc.description.sponsorshipLos autores
dc.identifier.otherdoi.org/10.1186/s13023-021-02162-z
dc.identifier.urihttp://hdl.handle.net/20.500.11764/4912
dc.language.isoen
dc.publisherLos autores
dc.relation.ispartofseriesOrphanet Journal of Rare Diseases; v. 17:13 2022
dc.subjectLIPOFUSCINOSIS CEROIDEAS NEURONALES
dc.subjectEnfermedades por Almacenamiento Lisosomal
dc.titleNeuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience
dc.typeArticle

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
29 s13023-021-02162-z.pdf
Tamaño:
845.94 KB
Formato:
Adobe Portable Document Format

Bloque de licencias

Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
85 B
Formato:
Item-specific license agreed upon to submission
Descripción: